165.50
-2.22 (-1.32%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Bearish | Bearish |
| Medical Instruments & Supplies (Global) | Mixed | Bearish | |
| Stock | Repligen Corporation | Bearish | Mixed |
Analyst Consensus
2 Buy
Avg. Price @ Call: 179.86
|
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Growth |
| 52 Weeks Range |
110.45 - 211.13
|
|
| Price Target Range | ||
| High | 207.00 (Stifel, 25.08%) | Buy |
| Median | 203.50 (22.96%) | |
| Low | 200.00 (JP Morgan, 20.85%) | Buy |
| Average | 203.50 (22.96%) | |
| Total | 2 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 02 May 2024 | 200.00 (20.85%) | Buy | 166.31 |
| Stifel | 22 Feb 2024 | 207.00 (25.08%) | Buy | 193.40 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GEBSKI CHRISTINE | - | 172.48 | -334 | -57,608 |
| KURIYEL RALF | - | 172.48 | -534 | -92,104 |
| Aggregate Net Quantity | -868 | |||
| Aggregate Net Value ($) | -149,713 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 172.48 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KURIYEL RALF | Officer | 14 May 2024 | Disposed (-) | 534 | 172.48 | 92,104 |
| GEBSKI CHRISTINE | Officer | 14 May 2024 | Disposed (-) | 334 | 172.48 | 57,608 |
| Date | Type | Details |
|---|---|---|
| 07 May 2024 | Announcement | Repligen Corporation to Present at Upcoming May Investor Conferences |
| 01 May 2024 | Announcement | Repligen Reports First Quarter 2024 Financial Results |
| 17 Apr 2024 | Announcement | Repligen to Report First Quarter 2024 Financial Results |
| 19 Mar 2024 | Announcement | Repligen Appoints Maggie A. Pax to Board of Directors |
| 21 Feb 2024 | Announcement | Repligen Reports Fourth Quarter and Full Year 2023 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |